Changes in Hong Kong stocks | Kangfang Biotech (09926) rose more than 5%, and cardonilizumab achieved positive PFS and OS results in 1L R/M cervical cancer phase 3 clinical trials

The Zhitong Finance App learned that Kang Fang Biotech (09926) rose by more than 5%. As of press release, it had risen 5.61% to HK$69.5, with a turnover of HK$140 million.

According to the news, on October 16, Kang Fang Biotech announced the detailed PFS and OS double positive results of the Phase III clinical study (AK104-303/COMPASSION-16) of cardonilizumab (AK104) compared placebo plus platinum-containing chemotherapy with/without bevacizumab to treat 1L of persistent, recurrent, or metastatic cervical cancer at the same time at the 2024 International Gynecological Cancer Society Global Conference and “The Lancet”.

CICC released a research report stating that the COMPASSION-16 data is positive and is expected to reshape the 1L cervical cancer treatment pattern. According to the company announcement, a total of 445 patients were enrolled in the study, with PD-L1 CPS<1 (negative expression) accounting for 26%, which is consistent with the expression level distribution of patients in the ITT group. MPFS 12.7m vs 9.1m, HR = 0.62; MoS NR vs 22.8m, HR = 0.64; 24-month OS rate 62.6% vs 48.4%, with significant differences in both PFS and OS. Furthermore, as the follow-up period was further extended (as of April 30, 2024), MPFs for the trial group and control group were updated to 13.3 months and 8.2 months (HR 0.62), further highlighting the clinical benefits.